A detailed history of Bridgeway Capital Management, LLC transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 48,000 shares of EYPT stock, worth $383,040. This represents 0.01% of its overall portfolio holdings.

Number of Shares
48,000
Previous 54,100 11.28%
Holding current value
$383,040
Previous $1.12 Million 62.7%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$8.16 - $22.89 $49,776 - $139,629
-6,100 Reduced 11.28%
48,000 $417,000
Q1 2024

May 15, 2024

SELL
$19.93 - $29.71 $376,677 - $561,519
-18,900 Reduced 25.89%
54,100 $1.12 Million
Q4 2023

Feb 14, 2024

SELL
$5.71 - $24.13 $251,811 - $1.06 Million
-44,100 Reduced 37.66%
73,000 $1.69 Million
Q3 2023

Nov 14, 2023

SELL
$7.99 - $15.36 $279,650 - $537,600
-35,000 Reduced 23.01%
117,100 $935,000
Q2 2023

Aug 14, 2023

BUY
$3.03 - $9.0 $369,963 - $1.1 Million
122,100 Added 407.0%
152,100 $1.32 Million
Q1 2023

May 15, 2023

BUY
$2.28 - $5.04 $68,400 - $151,200
30,000 New
30,000 $88,000
Q2 2022

Aug 15, 2022

SELL
$7.25 - $12.71 $250,125 - $438,495
-34,500 Reduced 57.12%
25,900 $204,000
Q1 2022

May 16, 2022

SELL
$8.67 - $14.11 $259,233 - $421,889
-29,900 Reduced 33.11%
60,400 $734,000
Q4 2021

Feb 14, 2022

SELL
$10.18 - $18.4 $229,253 - $414,367
-22,520 Reduced 19.96%
90,300 $1.11 Million
Q3 2021

Nov 15, 2021

SELL
$7.51 - $11.72 $127,670 - $199,240
-17,000 Reduced 13.1%
112,820 $1.18 Million
Q2 2021

Aug 16, 2021

BUY
$8.69 - $11.08 $152,083 - $193,911
17,501 Added 15.58%
129,820 $1.17 Million
Q1 2021

May 17, 2021

BUY
$8.89 - $14.92 $519,176 - $871,328
58,400 Added 108.31%
112,319 $1.14 Million
Q4 2020

Feb 16, 2021

BUY
$3.7 - $6.58 $199,500 - $354,787
53,919 New
53,919 $355,000

Others Institutions Holding EYPT

About EyePoint Pharmaceuticals, Inc.


  • Ticker EYPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,072,200
  • Market Cap $272M
  • Description
  • EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...
More about EYPT
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.